Back Bay Life Science Advisors’ Post

Our #MarketUpdate report for the week ending January 26th is now available. Highlights include:    ➡️ The Dow and S&P 500 both hit record highs this past week thanks in large part to a faster-than-expected GDP growth of 2.5% for the full 2023 calendar year     ➡️ IPOs are officially back – last week saw the first healthcare IPOs of 2024 price as three companies completed their listings, raising an aggregate $1.2B     ➡️ Two biotech companies – CG Oncology and ArriVent Biopharma raised $380.0M and $175.0M respectively for their late-stage cancer therapies on the Nasdaq     ➡️ BrightSpring Health Services, a healthcare service provider, raised $633.0M on the Nasdaq     ➡️ Sanofi made headlines with their $2.2B acquisition of Inhibrx, Inc., adding a potential best-in-class rare disease asset targeting Alpha-1 Antitrypsin Deficiency to their pipeline     ➡️ Venture investments saw an uptick in activity, with 13 private financings completed    Read the full update here: https://bit.ly/4bb0hsG       #HealthcareMarket #oncology #raredisease 

Our #MarketUpdate report for the week ending February 9th is now available. Highlights include:    ➡️US equities continued to rally as the S&P 500 broke the 5,000 threshhold for the first time thanks to strong tech earnings and a better-than-expected January jobs report    ➡️Biotech IPOs continue to be active so far in 2024 with two additional companies completing their listings:    ➡️Kyverna Therapeutics raised $319.0M to fund their Phase 2 autoimmune cell therapy candidate    ➡️Metagenomi raised $93.8M to fund their preclinical gene-editing assets targeting a variety of indications    ➡️Last week saw two notable M&A deals announced:    ➡️Novo Holdings made headlines with their $16.5B acquisition of Catalent Pharma Solutions, a deal that will give Novo Nordisk additional manufacturing sites to increase the production of their highly popular obesity and diabetes drugs    ➡️Novartis announced that they had entered into an agreement to acquire MorphoSys AG for $2.9B, further strengthening their oncology pipeline    Read the full update here: https://bit.ly/42zh58M     #HealthcareMarket #oncology #gene #autoimmune #IPO #MarketTrends #BBLSA 

Our #MarketUpdate report for the week ending February 23rd is now available. Highlights include:    ➡️With markets heating up, prioritizing fundamentals in biotech investing ensures resilience against volatility and sustains long-term growth amidst dynamic market conditions    ➡️US equities continued to rally as the S&P 500 and Dow closed at all-time highs on Friday    ➡️Iovance Biotherapeutics, Inc. announced a $211.0M follow-on offering to fund the commercial launch of AMTAGVI, a novel polyclonal tumor-infiltrating lymphocyte therapy for the treatment cancer, in addition to current clinical trials    ➡️Ocular Therapeutix, Inc. made headlines by announcing a $325.0M PIPE to fund the clinical development of AXPAXLI, a hydrogel implant for the treatment of wet age-related macular degeneration (AMD), making this the largest PIPE/RDO announced in 2024 to-date    ➡️M&A and licensing transactions saw a decrease in activity relative to 2024 to-date as only two licensing deals were announced    Read the full update here: https://bit.ly/3SRPjQC     #healthcare #markettrends #cancertreatments #clinicaltrials #therapeutics #Biotech #BBLSA  

Private equity investment in clinical trial site networks and the accompanying M&A growth strategy have seen a significant uptick since mid-2023. Corporate development executives who can apply their expertise to this space will play a crucial role in driving the success of these organizations. #PrivateEquity #Investment #ClinicalTrials #CorporateDevelopment #GrowthStrategy

Recent increase in M&A activity (wave of biotechs takeovers), stock rebound in December (fueled by expectations that the Federal Reserve will cut interest rates this year) and significant unspent cash from private equity firms... an interesting 2023 landing in the run up to the JPMorgan Conference this week.

Our #MarketUpdate report for the week ending February 2nd is now available. Highlights include:    🔉 Despite the Fed’s meeting minutes revealing that March rate cuts are unlikely, US equities ended the week with gains thanks to strong tech earnings    🔉 Biotech IPOs continue to build momentum as Alto Neuroscience and Fractyl Health both completed their upsized listings, raising $128.6M and $110M, respectively    🔉 Vaxcyte made headlines, completing a $700M follow-on offering to fund the development of their novel protein vaccines used to prevent or treat bacterial infectious diseases    🔉 M&A, licensing, and venture deals saw a slight decrease in the volume of deal-making relative to 2024 to date    Read the full report here: https://bit.ly/4bmQFv4     #HealthcareMarket #IPO #InfectiousDisease  

Check out our research on Q1 2024 healthcare and life sciences overview. What were the top R&D partnerships? We discuss M&A, venture activity and IPOs. https://hubs.ly/Q02twDBx0

We've definitely seen significant slowdown in IPO and M&A activity over the last few months. The year started off with a decent flurry of activity, but the brakes have definitely been pulled. Here's a decent rundown of the highlights in the space over the last 3 months, worth taking a look. Feels like the upcoming election, BIOSECURE and Inflation Reduction Act are causing a pause in the market here. https://lnkd.in/gnfc9iQF

As the #UNGA meets to discuss anti-microbial resistance, Tenmile has made an investment in Lumos Diagnostics, furthering our commitment to support commercial efforts to stem the threat of #AMR. How does Lumos play a role in this fight? About a month ago, there was a case of whooping cough (caused by Bordetella pertussis, a bacterial infection) in my daughter's pre-school. A week later my daughter started coughing and we promptly visited our GP. While the GP felt it was unlikely to be bacterial, the definitive test would take 2-3 days and so to be safe, recommended #antibiotics. As a parent, it's hard not to take this advice and promptly started antibiotic treatment. Three days later we got the news that it was not a bacterial infection. There was no need for antibiotics, yet we've already exposed our daughters microbiome out of caution, becoming a part of a scary statistic. Approximately 30% of antibiotics are prescribed when they aren't necessary. This is where FebriDx steps in. Lumos has developed FebriDx as a point-of-care diagnostic to distinguish bacterial from non-bacterial infections. In 10 minutes, a GP could have identified that my daughter's cough was not caused by a bacterial infection and that antibiotics would not help. Along with novel antibiotics (Revagenix, Inc.) and vaccines (LimmaTech Biologics AG), #diagnostics will play a key role in identifying bacterial infections, avoiding over-prescription and reducing the burden of AMR.

A really useful article from my colleagues Jonathan GREENWOOD and Katharine Robinson Although it's framed in the biotech space, I think the useful tips in this post apply for any business owners contemplating an exit. So if that's you - it's definitely worth a read. #MergersAndAcquisitions #PrivateEquity #DealMaking #BusinessOwner #Entrepreneurs